|1.||van Amsterdam, R G: 1 article (10/2000)|
|2.||van Dinther, T G: 1 article (10/2000)|
|3.||Vogel, G M: 1 article (10/2000)|
|4.||Tromp, M: 1 article (10/2000)|
|5.||Meuleman, D G: 1 article (10/2000)|
10/01/2000 - "The results indicate that the novel drug Org 36764 is a drug with antithrombotic potential against venous and arterial thrombosis."
10/01/2000 - "Org 36764 was more active in suppressing in vivo thrombus formation on stents than UFH. "
10/01/2000 - "Org 36764 was more active than the pentasaccharide SanOrg 34006 (= AT binding domain of Org 36764) in arterial thrombosis, but both were equally active in venous thrombosis. "
10/01/2000 - "In arterial thrombosis following endothelial damage by ferric chloride, Org 36764 was more active than the LMW heparin enoxaparin and SanOrg 34006 and similar active to UFH. "
|2.||Venous Thrombosis (Deep-Vein Thrombosis)
10/01/2000 - "It displays in buffer an anti-Xa and anti-thrombin activity of 415 and 2 U/mg, respectively, compared to 172 and 114 U/mg, respectively, for unfractionated heparin (UFH), Org 36764 does not cross-react with HIT (heparin induced thrombocytopenia) antibodies and is not neutralised by PF4. "